期刊文献+
共找到7篇文章
< 1 >
每页显示 20 50 100
An exceptional case of myelodysplastic syndrome with myelofibrosis following combination chemotherapy for squamous cell lung cancer
1
作者 Yi-Hao Wang Rong Fu Zong-Hong Shao 《Cancer Biology & Medicine》 SCIE CAS CSCD 2013年第2期117-120,共4页
A 60-year-old woman with squamous cell carcinoma in the right lung was successfully treated with four cycles of combination chemotherapy after surgery, and complete remission was achieved. However, the patient develop... A 60-year-old woman with squamous cell carcinoma in the right lung was successfully treated with four cycles of combination chemotherapy after surgery, and complete remission was achieved. However, the patient developed myelodysplastic syndrome (MDS) RAEB-2 with myelofibrosis after remission, possibly because of chemotherapy or DNA methylation. The patient responded well to dacitabine (Dacogen), suggesting that DNA hypomethylation agents can be a promising therapy to retard the progression of a second tumor or carcinoma. 展开更多
关键词 DNA methylation myelodysplastic syndrome MYELOFIBROSIS squamous cell lung cancer
下载PDF
Acute myocardial infarction mimicking squamous cell lung cancer with bone metastases due to hypercalcemia: a case report
2
作者 FANG Chong-feng XU Geng CHEN Yang-xin 《Chinese Medical Journal》 SCIE CAS CSCD 2010年第3期369-371,共3页
Acute myocardial infarction (AMI), the most severe .coronary artery disease, is one of the most frequent cardiac emergencies, and early diagnosis and treatment are very important to decrease the subsequent cardiac a... Acute myocardial infarction (AMI), the most severe .coronary artery disease, is one of the most frequent cardiac emergencies, and early diagnosis and treatment are very important to decrease the subsequent cardiac adverse events such as malignant arrhythmia and sudden cardiac death. But in fact, lots of diseases are similar to AMI in clinical practice, of which the most common are myocarditis, pulmonary embolism in department of cardiology. Here we report a case of AMI-like squamous cell lung cancer with bone metastases. 展开更多
关键词 acute myocardial infacrtion squamous cell lung cancer HYPERCALCEMIA neoplasm metastases
原文传递
ROS1 in Squamous Non-Small Cell Lung Cancer—Combined Immunotherapy (PD1/CTLA4) or Targeted Therapy?
3
作者 Alexander Yakobson Tal Mor +7 位作者 Levitas Dina Laila C. Roisman Daniel Levin Wafeek Alguayn Sara Morgenstern Keren Rouvinov Nir Peled Waleed Kian 《Journal of Cancer Therapy》 2020年第6期365-370,共6页
ROS1 oncogenic fusion is reported to be 1%</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"... ROS1 oncogenic fusion is reported to be 1%</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> - </span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;">2% of non-small cell lung cancers (NSCLCs) of the adenocarcinoma subgroup. Meanwhile, there are no records of squamous cell cancer patients with tumors harboring ROS1 fusions. The Foundation Medicine database indicates a frequency of ROS1 rearrangements is 0.2% among squamous NSCLC. Crizotinib is known to be very effective in these patients</span><b><span style="font-family:Verdana;">.</span></b></span></span></span><span><span><b><span style="font-family:""> </span></b></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">Here we present a non-smoker patient who had pure squamous NSCLC that was treated by combinational immunotherapy under a clinical trial and progressed after 2 cycles. Surprisingly, comprehensive genomic profiling detected a rare oncogenic EZR-ROS1 fusion, and the patient was treated by crizotinib with a significant response within 6 weeks. To date, the patient has been on therapy for 42 months</span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">and has achieved</span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">a complete metabolic response. 展开更多
关键词 ROS1 CRIZOTINIB squamous cell lung cancer IMMUNOTHERAPY Non-Small cell lung cancer
下载PDF
Rapid killer:Lung squamous cell cancer
4
作者 Maria Mitri Samer F.Nehme 《Discussion of Clinical Cases》 2021年第2期11-13,共3页
Background:Lung cancer is one of the leading causes of death despite improvement in treatment modalities such as immunotherapy with chemotherapy and precise radiotherapy.NSCLC is a heterogeneous group of diseases that... Background:Lung cancer is one of the leading causes of death despite improvement in treatment modalities such as immunotherapy with chemotherapy and precise radiotherapy.NSCLC is a heterogeneous group of diseases that differs in cytology and includes adenocarcinoma,squamous cell carcinoma,bronchioloalveolar carcinoma,and poorly differentiated carcinoma.Usually,NSCLC,in contrast to SCLC,spreads locally,and the doubling time of squamous cell carcinoma is 133 days which classifies it as a relatively slow-growing tumor.Case presentation:We present the case of a 72-year-old male,recently diagnosed with squamous cell carcinoma in the right upper lobe along with secondary deposits.Few days after diagnosis,the patient had severe respiratory distress.This endobronchial tumor has increased significantly in size upon bronchoscopic visualization causing a complete obstruction of his right main bronchus and hypoxemic respiratory failure requiring intubation.Conclusion:To our knowledge,there are few reported cases where lung adenocarcinoma progressed rapidly over days.Squamous cell carcinoma usually takes 3 to 6 months to double in size,but in our case,the progression was very fast.In the last decade,it was confirmed that the doubling time of a tumor is an independent factor in the prognosis of lung cancer patients.On the other hand,further studies are needed to identify genes associated with rapid progression and a worse prognosis for lung squamous cell carcinoma.Hence,this aggressive tumor is a“rapid killer.” 展开更多
关键词 lung cancer Hypoxemic respiratory failure BRONCHOSCOPY White lung squamous cell lung cancer Volume doubling time
下载PDF
CUL4 E3 ligase regulates the proliferation and apoptosis of lung squamous cell carcinoma and small cell lung carcinoma 被引量:4
5
作者 Ting Li Si Wu +4 位作者 Lei Jia Wenfeng Cao Yuan Yao Gang Zhao Hui Li 《Cancer Biology & Medicine》 SCIE CAS CSCD 2020年第2期357-370,共14页
Objective:The E3 ligase,CRL4,plays diverse roles in different cellular processes,such as DNA damage,transcriptional regulation,cell cycle progression,and cell apoptosis.Our previous study showed that CUL4A and CUL4B h... Objective:The E3 ligase,CRL4,plays diverse roles in different cellular processes,such as DNA damage,transcriptional regulation,cell cycle progression,and cell apoptosis.Our previous study showed that CUL4A and CUL4B had a strong association with tobacco smoking risk in lung squamous cell carcinoma(SCC)and small cell lung carcinoma(SCLC).This study aimed to define the potential mechanism underlying the roles of CUL4A and CUL4B in the development of SCC and SCLC.Methods:We determined the role of CUL4A and CUL4B in the cell cycle and apoptosis of SCC and SCLC,and identified the key apoptosis-related gene involved in the oncogenic activity of CUL4B by Western blot,immunohistochemical staining,flow cytometry,and enzyme inhibition experiments.Results:We found that depletion of CUL4A and CUL4B reduced the proliferation of SCC and SCLC cells.cUL4Aknockdown but not CUL4Bknockdown arrested cells in Gl phase while upregulating P21 and cU L4Bknockdown promoted cell apoptosis through upregulation o f FOXO3A.Accordingly,CUL4B decreased FO X03A expression by activating the ERK signaling pathway and mediating FOXO3A degradation via the ubiquitin-proteasome pathway.Conclusions:These results identified the function of E3 ligase CRL4 in regulating SCC and SCLC cell proliferation,which provides a potential strategy for cancer therapy by targeting FOXO3A and the E3 ligase,CRL4. 展开更多
关键词 squamous cell lung cancer small cell lung cancer CUL4A CUL4B P21 FOXO3A
下载PDF
Immunotherapy – new perspective in lung cancer 被引量:4
6
作者 Fillipe Dantas Pinheiro Adriano Fernandes Teixeira +3 位作者 Breno Bittencourt de Brito Filipe Antonio Franca da Silva Maria Luísa Cordeiro Santos Fabrício Freire de Melo 《World Journal of Clinical Oncology》 CAS 2020年第5期250-259,共10页
Lung carcinoma is associated with a high mortality worldwide,being the leading cause of cancer death.It is mainly classified into squamous non-small cell lung cancer(NSCLC),non-squamous NSCLC,and small cell lung cance... Lung carcinoma is associated with a high mortality worldwide,being the leading cause of cancer death.It is mainly classified into squamous non-small cell lung cancer(NSCLC),non-squamous NSCLC,and small cell lung cancer.However,such malignancy has been increasingly subdivided into histological and molecular subtypes to guide treatment.Therapies can be used in adjuvant and palliative settings.Regarding immunotherapy,it has been widely tested in both first or subsequent palliative lines.In this sense,drugs such as pembrolizumab,nivolumab,atezolizumab,ipilimumab,avelumab,and durvalumab have been assessed in large studies.Some of these trials have also studied these medicines in adjuvant and in maintenance therapy.In recent years,advances in immunotherapy have raised the hope that the unfavorable prognosis observed in several affected individuals can be changed.Immunotherapy has increased the overall survival in squamous NSCLC,non-squamous NSCLC,and small cell lung cancer.However,it has added to the oncology practice some side effects that are unusual in standard chemotherapy and require special clinical support.In order to show how immunotherapy is being applied in the treatment of lung carcinoma,we reviewed the main studies in adjuvant and palliative scenarios.What is the better scheme?What is the better combination?What is the better dose?When should we use immunotherapy?Does programmed cell death ligand 1 expression significantly interfere in immunotherapy efficiency?Some of these questions have already been answered,while others require more investigations. 展开更多
关键词 lung cancer Treatment IMMUNOTHERAPY squamous non-small cell lung cancer Non-squamous non-small cell lung cancer Small cell lung cancer
下载PDF
Adenocarcinoma transformed into squamous cell carcinoma in non-small cell lung cancer 被引量:2
7
作者 Yueqiang Jiang Jun Zhang +7 位作者 Jin Feng Yaping Lu Yuan Fan Ling Cheng Xin Liao Liya Hu Shiying Yu Tiejun Yin 《Journal of Genetics and Genomics》 SCIE CAS CSCD 2021年第7期656-659,共4页
Non-small cell lung cancer(NSCLC)is the most common form of lung cancer which remains the deadliest malignancy worldwide(Siegel et al.,2019).In general,NSCLC can be divided into several subtypes,including adenocarcino... Non-small cell lung cancer(NSCLC)is the most common form of lung cancer which remains the deadliest malignancy worldwide(Siegel et al.,2019).In general,NSCLC can be divided into several subtypes,including adenocarcinoma(ADC),squamous cell carcinoma(SCC),adeno-squamous cell carcinoma(AD-SCC)and large cell carcinoma(LCC). 展开更多
关键词 ADC Adenocarcinoma transformed into squamous cell carcinoma in non-small cell lung cancer
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部